Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy? Patients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L.

Trial Details

NCT ID
NCT05852990
Phase
PHASE3
Sponsor
Instituto Nacional de Cancerologia de Mexico
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Glutamine plus L. reuteri
Locations (sample)
  • Mexico City, Mexico City, Mexico|19.42847,-99.12766

Key Eligibility Criteria

  • Both sexes
  • ≥ 18 years old
  • Pathologically confirmed diagnosis of NSCLC
  • Stage IIIB - IV by the American Joint Committee of Cancer Version 8.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →